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Abstract
The clinical importance of monitoring liver fibrosis lies in the morbidity and 
mortality of the chronic liver diseases in relation to the stage and progression of 
fibrosis. Whether the fibrosis stabilizes or regresses depends on the specific treat-
ment. Liver biopsy, the current standard for the diagnosis, has implicit limitations 
due to sampling heterogeneity. There are noninvasive imaging methods, such as 
transient elastography that measures the stiffness of the liver, but it has some limita-
tions (feasibility and unreliability), particularly in obese patients. FibroTest is the 
most widely used noninvasive serological method worldwide which is efficacious in 
the extreme stages of fibrosis, but these methods cannot discern intermediate stages. 
Liver fibrosis is a dynamic response that involves multiple cellular and molecular 
events with an excessive deposit of extracellular matrix. Even though there is much 
information on the pathophysiology of fibrosis, that knowledge is still incomplete, 
greatly hindering the development of both an accurate treatment and a noninvasive 
diagnostic method with adequate sensitivity for all the stages of fibrosis. It is known 
that IGFBP participates in liver homeostasis, and thus these proteins can be used as 
serum biomarkers during the progression of liver fibrosis in chronic hepatitis C.
Keywords: liver fibrosis, inflammation, fibrolysis, noninvasive diagnosis
1. Introduction
The etiologic factors that mainly induce liver fibrosis are alcoholic liver disease 
(ALD), chronic hepatitis C (CHC), and nonalcoholic fatty liver disease (NAFLD). 
Fibrogenic response can be organized in four different phases according to dam-
age evolution: activation, production of extracellular matrix proteins (ECM), and 
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deposition and degradation of ECM by hepatic stellate cells (HSCs) [1]. The inef-
ficient resorption and control of ECM components promote the establishment and 
progression of fibrosis inducing the distortion in the architecture of the hepatic 
parenchyma.
Moreover, the regulation of wounding response is orchestrated by complex 
activities within different cells that include HSC, macrophages, myofibroblasts, 
cells derived from bone marrow, and fibrocytes [1–3]. The main type of ECM 
proteins produced by HSC comprises collagens, fibronectin, laminin, hyaluronan, 
proteoglycan, and other elements [3, 4]. It has been extensively reported that liver 
fibrosis progresses to cirrhosis in 20% of patients; furthermore, if the damage is not 
controlled, approximately 10% of people can progress to carcinoma hepatocellular, 
which usually causes death in all the cases [5].
The clinical importance of monitoring liver fibrosis progression is correlated 
with the reduction of morbidity and mortality of the chronic liver diseases [6]. 
Whether the fibrosis stabilizes or regresses depends on the specific treatment of 
the underlying disease, and the grade of fibrosis is a treatment indicator [4]. The 
clinical evidence documenting the fate of HSC during fibrosis regression in humans 
is limited, compared to the extensive evidence in animal models [4, 6, 7]. Promising 
studies showed strong evidence that the opportune and precise identification of 
the etiology and degree of liver fibrosis could be crucial for decision-making in the 
management and treatment.
Liver biopsy has been considered the keystone for the diagnosis of fibrosis and 
inflammation, necrosis, and iron deposition [8]; however, this invasive procedure 
has implicit important limitations due to sampling heterogeneity and possible surgi-
cal complications, variability in the interpretation by pathologists, elevated costs, 
and the difficulty of tracking the evolution of the disease [9, 10]. Furthermore, 
biopsy is not recommended in patients with ascites, coagulopathy, diabetes, meta-
bolic syndrome, and ALD [11–13]. For these reasons, in the last years, the medical 
and research groups have evaluated novel noninvasive strategies to discriminate the 
liver pathologies.
2. Diagnosis of liver fibrosis
Noninvasive measures of liver fibrosis have streamlined the management 
of patients with CHC [6]. Imageology methods, such as transient elastography 
(FibroScan™), which measures the stiffness of the liver, have received great 
acceptance by clinicians and patients. Clinical trials showed that FibroScan results, 
which are expressed in kPa, reported similar results to that of METAVIR score 
during biopsy interpretation of liver fibrosis in patients with CHC [10]. Moreover, 
this procedure has also been validated in chronic hepatitis B, NAFLD, alcoholic liver 
disease, primary biliary cirrhosis, and primary sclerosing cholangitis  
[14, 15]. However, this methodology also has some limitations such as feasibil-
ity and unreliability, particularly in obese patients or under the circumstances of 
limited operator experience [16]. Furthermore, it is important to consider that 
this strategy is contraindicated during pregnancy, ascites, and implanted cardiac 
pacemaker patients [10].
A variety of “direct” serum markers reflecting ECM turnover (fibrogenesis and 
fibrolysis) and/or fibrogenic cell changes have been developed and used clinically 
[17]. In this sense, the multiple analyses of proteins and clinical trials provide valu-
able information of liver stage. FibroTest index is within the most accepted world-
wide noninvasive serological method in the diagnosis of liver fibrosis by CHC, 
CHB, and NAFLD [17]. For this analysis are computed five surrogate parameters: 
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total bilirubin, haptoglobin, gamma-glutamyltranspeptidase (GGT), alpha2-
macroglobulin, and apolipoprotein-A. It is important to mention that the valida-
tion of any surrogate parameter needs to be validated by the calculation of the 
area under the receiver operating characteristic curve (AUROC) using liver biopsy 
as reference [8]. Systematic analysis of several studies revealed that FibroTest 
displayed an excellent discrimination to identify cirrhosis with AUROC = 0.90 but 
showed a lesser ability to identify ≥F2 fibrosis stages (AUROC = 0.81). The authors 
conclude that this index is not ready to substitute liver biopsy in the intermediate 
stages [18]. Additionally, some limitations such as cost and external validation are 
documented.
Even though there is much information on the pathophysiology of fibrosis, 
that knowledge is still incomplete, greatly hindering the development of both an 
accurate treatment and a noninvasive diagnostic method with adequate sensitivity 
for all the stages of fibrosis. Such a method must also be able to be performed with 
the necessary frequency to establish disease progression or regression, as well as the 
changes that occur in the processes, such as chronic inflammation, fibrogenesis, 
and fibrolysis. Based on our knowledge of fibrosis pathogenesis, attention is now 
directed towards strategies for antifibrotic therapies and regulatory challenges for 
conducting clinical trials with these agents. New therapies are attempting to: (1) 
control or cure the primary disease or reduce tissue injury; (2) target receptor-
ligand interactions and intracellular signaling; (3) inhibit fibrogenesis; and (4) 
promote resolution of fibrosis. Progress is urgently needed in validating noninva-
sive markers of fibrosis progression and regression that can supplant biopsy and 
shorten the duration of clinical trials. Both scientific and clinical challenges remain, 
however, in the past three decades of steady progress in knowledge liver fibrosis.
This entails analyzing the molecules involved in these processes along with 
the participation of proteins such as insulin-like growth factor binding proteins 
(IGFBPs). Recently, IGFBP-1 and insulin-like growth factor (IGF) have been 
proposed as markers for advanced fibrosis in NAFLD [19]. However, the completed 
evaluation of IGFBPs in liver diseases is not fully understood.
3. Insulin-like growth factor (IGF) complex
The IGF is a family of proteins with high sequence homology to insulin. The 
IGF system functions as an endocrine, paracrine, and autocrine regulatory axis for 
cell proliferation, survival, and apoptosis in different types of cells [20]. In general, 
the IGF system consists of two surface receptors (IGF1R and IGF2R), two ligands 
(IGF-1 and IGF-2), and a family of IGFBPs [20, 21].
Liver is the main source of IGFs but its highest concentrations are found in the 
blood. Both IGF-1 and -2 forms can be detected in small amounts in the kidney and 
other tissues of different species, for example, in the rat, IGF-I has been detected 
in serum, milk, amniotic fluid, and bile; it has also been detected in human adult 
bile [22]. In some experiments, it has been found that IGF-1concentrations are 
higher in bile of neonatal rats than in the adult rats. Thus, it is believed that IGF-I 
in bile should have an important role in the development of gastrointestinal tract. 
However, the precise role and the presence or absence of IGFs and IGFBPs in bile 
have not yet been clearly defined. The biosynthesis of IGFs depends mainly on 
the levels of growth hormone (GH), insulin, prolactin, and an adequate nutrition 
stimulus. In contrast, estrogens and cortisol can antagonize their formation [23].
The production of IGF-1 is stimulated by GH, which is secreted by somato-
tropic cells in the adenohypophysis. The hepatocytes present GH receptors that are 
stimulated by this hormone and in a consequence an increase in the transcription of 
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the IGF-1 gene is triggered. IGF-1 inhibits GH secretion either directly acting on the 
pituitary or indirectly by stimulating the hypothalamic secretion of somatostatin 
which, in turn, inhibits the release of GH. In this way, a negative feedback loop 
GH-IGF-1 is established [21, 23].
IGFBPs play important roles in the bioavailability of circulating IGF-I, and their 
synthesis is under metabolic and hormonal control. Their functions can be sum-
marized as follows: (1) they act as protein carriers in serum and control the influx 
of IGF-I from the vascular space to the tissues. (2) They prolong the half-life of 
IGF-I and regulate its metabolism. (3) They provide temporal localization of IGF-1 
with the aim to be available under specific requirements. (4) They modulate the 
interaction of IGF-I with its receptor, thus acting as indirect control of the biologi-
cal actions of IGF-I.
At present, different types of IGFBPs have been described that are mainly pro-
duced by hepatocytes and secreted into the blood serum. They can be a high affinity 
for binding IGFs (IGFBP-1 to IGFBP-6) or a low affinity (IGFBP-7 among others). 
Normal serum IGF-I levels are approximately 40 nmol/L, and 99% of circulating 
IGF-Iis was estimated to be associated with the different IGFBPs, mainly IGFBP-3 
[23–25].
In recent years, these proteins have gained great attention due the association as 
biomarkers in different pathologies [25].
4. IGFBPs and liver fibrosis
An increase in IGFBP-1 levels has been observed during nonalcoholic liver dis-
ease and cirrhosis of the liver. At the same time, serum IGFBP-3 concentrations are 
low, correlating with the severity of liver dysfunction, and signifying poor progno-
sis in hepatocellular carcinoma (HCC) [26]. In in vitro studies, IGFBP-7 expression 
has been found to hepatocyte apoptosis and HSC activation [27, 28]. In relation to 
the participation of IGFBP-2, -5 and -6, there is little evidence of their concentra-
tions in serum and the possible association with liver diseases. Nevertheless, those 
proteins can inhibit angiogenesis (IGFBP-4) [29], regulate the role of TNF-α, tumor 
growth, and an increased expression in pulmonary and liver fibrosis (IGFBP-5) [30, 
31] and promote prostate cancer cell migration (IGFBP-6) [22, 32]. The available 
information about the role, tissue production, and dependent and independent 
functions of IGFBPS as well as their regulation in related liver pathologies is 
resumed in Table 1.
In the present work, we include recently obtained data in our laboratory of a 
prospective comparative multicenter study to evaluate the production of IGFBPs 
according to liver fibrosis grade in patients with CHC. We provide a valuable and 
innovative approach to the analysis of IGFBPs as a group of proteins with important 
potential for improving diagnosis and maybe soon can be used as novel noninvasive 
biomarkers for liver fibrosis.
Even advanced stages of liver fibrosis have been described as reversible, stimu-
lating considerable research to identify molecules for the development of anti-
fibrotic therapies [35, 36].
IGFBPs are produced in the liver, but there is little evidence of their participa-
tion in the process of liver damage in humans. Their study can further improve 
the knowledge of liver fibrosis pathophysiology and enable the identification of 
therapeutic targets.
The aim of the present study was to measure the serum concentrations of the 
different IGFBPs in patients with CHC and analyze them according to the grade of 
fibrosis grade.
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5. Methods and patients for the study of IGFBPs in chronic hepatitis C
A prospective, cross-sectional, observational study was conducted. It included 
patients seen at the General Hospital of Mexico, University Hospital of Autonomous 
University of Nuevo Leon, and the National Institute of Medical Sciences and 
Nutrition, within the time frame of January 2011 to December 2015. The patients were 
treatment-naïve or untreated, and their grades of fibrosis were evaluated through 
Protein Production IGF-dependent 
functions
IGF-independent 
functions
Participation in 
liver
Ref.
IGFBP-1 Liver
Kidney
Endometrium
Amniotic fluid
Fetal plasma
Modulates 
cell growth, 
differentiation, and 
metabolism
Proliferation, 
migration, and 
apoptosis
↑ Hepatic cirrhosis
↑ F3-F4 in NAFLD
[19]
IGFBP-2 CNS
Liver
Heart
Kidney
Prostate
Adipocytes
Promotes the 
bioavailability of IGF 
to its ligands
Proliferation
It binds with TGF-β
Unknown [33]
IGFBP-3 Liver Form a ternary 
complex with IGF and 
acid-labile subunit 
(90%)
Survival
Activation of MAPK in 
pulmonary fibrosis
Interaction with 
TGF-β
↓ Cirrhosis, and HCC [26]
IGFBP-4 Liver
Heart
Bone
Ovary
Prostate
Kidney
Inhibits angiogenesis
Regulates bone 
formation
Tumor processes 
and in reproduction 
biology
Possible role in 
experimental liver 
regeneration
[29, 
34]
IGFBP-5 Liver
Bone
Lung
Testicle
Ovary
Uterus
Placenta
Form a ternary 
complex with IGF and 
acid-labile subunit
Inhibits and promotes 
tumor growth
Inhibits the actions of 
TNF-α
Inhibits and promotes 
tumor growth
proliferation
↑Experimental 
Fibrosis
[30, 
31]
IGFBP-6 Liver
Lung
Intestine
CSN
Inhibits the actions of 
the IGF-II
Promotes the 
migration of cancer 
cell lines
Inhibition of 
angiogenesis
Unknown [22, 
32]
IGFBP-7 Liver Cell adhesion in 
cancer cells
Cell proliferation, 
differentiation, 
adhesion, senescence, 
apoptosis, and 
angiogenesis. Tumoral 
suppressor
Mutual regulation 
with TGF-β
↓HCC
↑ Experimental and 
clinical fibrosis
[27, 
28]
CNS: Central nervous system, HCC: Hepatocellular carcinoma, F3-F4: advanced stage of fibrosis, ↑ up-regulation 
and ↓ down-regulation.
Table 1. 
Proteins of the IGF system, IGFBPS production, functions, and their regulation in related liver pathologies.
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the FibroTest and FibroScan methods. According to fibrosis grade, the patients were 
divided into four groups: F0, F1-F2, F3, and F4. Given the small number of patients 
with stages F1 and F2, they were combined as a single group (n = 25). Patients with at-
risk alcohol consumption (AUDIT < 8) and whose fibrosis grade was not determined 
using the same diagnostic methods stated above were excluded. The control group 
was made up of healthy subjects, defined as persons that were not at-risk drinkers 
(AUDIT < 8) and had negative serology for hepatitis A, B, and C viruses (n = 160).
All participants signed statements of informed consent and the study protocol 
followed the ethics guidelines of the 1975 Declaration of Helsinki. Blood samples 
(10 mL) were taken from all participants. The serum was separated and stored at 
−80°C until its use. The anthropometric variables obtained for each study subject 
were: sex, age, height (measured in centimeters with a stadiometer), weight (mea-
sured in kilograms with a manual scale), and body mass index (BMI) (kilograms/
meters2; weight/height2 formula). The following biochemical tests were performed 
on all the study subjects: total bilirubin, direct bilirubin, aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT). A detailed clinical history was carried 
out for each patient, through which the presence of clinical data of liver damage 
was intentionally evaluated. IGFBP determination was carried out through multiple 
suspension array technology (Millipore®). The use of antibodies made it possible to 
study the concentration of a variable number of proteins in a single serum sample. 
Thus, seven proteins were analyzed in a single assay, reducing intra-assay and 
inter-assay error, %CV of <10 and of <15 for intra- and inter-assay, respectively, 
without cross-reactivity. The HIGFBMAG-53 K07 kit was employed. The data were 
acquired utilizing Luminex200 MAGPX® Systems equipment (series number 
10294005), following the supplier’s specifications. The sensitivity of the minimum 
and maximum detection values for each protein was obtained using Luminex 
XPONENT software. The continuous variables were described as mean ± standard 
deviation and the qualitative variables as absolute and relative frequencies (percent-
ages). The qualitative variables were analyzed using the chi-square test and ANOVA 
test, orthogonal analyses, and Spearman correlation was used for the quantitative 
variables. Statistical significance was set at p < 0.05. Logistic regression analysis 
with advanced fibrosis stage as the dependent variable was applied. Receiver 
operating curves (ROCs) were made. Statistical analysis was carried out using the 
SPSS version 22 program.
6. Clinical determinations
Demographic analysis showed the predominance of women in the group of 
CHC; furthermore, the age mean was 50 years in CHC in comparison with the mean 
of 37 years in CT. Nevertheless, body mass index (BMI) did not show differences in 
both groups of study. Liver function tests that include bilirubin and transaminases 
(AST and ALT) showed evident and significant increment of values that reflect the 
liver dysfunction in CHC patients (Table 1).
A total of 120 patients diagnosed with chronic hepatitis C (CHC) were included 
in the study. Many of the patients were women. All the patients were untreated and 
did not drink alcohol. The control population was made up of 165 healthy subjects 
with negative viral panels and no at-risk alcohol consumption (Table 2).
6.1 Serum determination of IGFBP proteins
As was previously mentioned, the multiple suspension arrangement (Luminex) 
was used to quantify the levels IGFBP-1 to IGFBP-7 proteins, both in serum of 
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patients with chronic liver disease and in CT. As we expected, a differential regula-
tion of IGFBPs through the different stages of fibrosis in CHC was observed.
6.1.1 IGFBP-1 to IGFBP-7 quantification
IGFBP-1 concentration (ng/mL) was higher in patients compared with controls 
(1.35 ± 0.26 and 0.65 ± 0.12, respectively, p = 0.02), as were the IGFBP-2 values 
(16.26 ± 3.81 vs. 3.91 ± 0.35, p = 0.002). IGFBP-3 had the highest concentrations of 
all the IGFBPs, with a tendency to be lower in patients (778 ± 36) than in controls 
(878 ± 40, p = 0.066). IGFBP-4 concentrations were higher in patients than in 
CHC (120) CT (165) P
Gender n (%)
Men 25 (29) 138 (89) <0.001
Women 95 (71) 27 (11)
Age (years) 51 ± 10 37 ± 9 <0.001
BMI (Kg/m2) 27 ± 4 28 ± 4 0.464
Total Bilirubin (mg/dl) 1.37 ± 0.22 0.78 ± 0.03 <0.001
Direct Bilirubin (mg/dl) 1.21 ± 0.16 0.68 ± 0.03 <0.001
AST (UI/I) 84 ± 7 30 ± 1 <0.001
ALT (UI/I) 90 ± 6 28 ± 2 <0.001
AST, aspartate amine transferase; ALT, alanine anime transferase. Data are expressed as mean ± standard deviation.
Table 2. 
Demographic data of study groups.
IGFBP
(ng/mL)
F0
(35)
F1–F2
(11–14)
F3
(21)
F4
(39)
CT
(165)
p
1 0.9 ± 0.5 1.5 ± 0.5 1 ± 0.5 1.4 ± 0.5 0.65 ± 0.12 NS
2
8.8 ± 8.4 10 ± 5 26 ± 9 18 ± 7 3.9 ± 3.5
F0vs.CT*
F1-F2vs.CT* 
F3vs.CT†
F4vs.CT†
3 695 ± 202 620 ± 350 844 ± 304 756 ± 391 878 ± 406 NS
4
25 ± 17 88 ± 76 37 ± 30 77 ± 29 21 ± 19
F1-F2vs.CT*
F3vs.CT*
F4vs.CT†
5
97 ± 71 237 ± 186 107 ± 36 324 ± 292 241 ± 118
F4vs.CT*
F0vs.F4†
F1-F2vs.F3†
6 136 ± 53 112 ± 68 168 ± 81 126 ± 59 122 ± 42 NS
7
20 ± 10 42 ± 30 91 ± 23 60 ± 42 33 ± 31
F3vs.CT†
F4vs.CT†
F0vs.F3†
F0vs.F4*
F1-F2vs.F3*
F3vs.F4*
Data are expressed as mean ± standard error (SE). *p < 0.05; † p < 0.005.
Table 3. 
Concentration of IGFBP 1 to 7 and fibrosis stages in patients and control groups.
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controls (59 ± 14 vs. 21 ± 1.9, p = 0.008). IGFBP-5 values were similar between 
patients and controls (251 ± 26 vs. 241 ± 21, p = 0.786), as were IGFBP-6 concentra-
tions (131 ± 6.6 vs. 122 ± 4.2, p = 0.244). IGFBP-7 concentrations were higher in 
patients (57 ± 4.4), compared with controls (33 ± 3.1) (p < 0.001).
6.1.2 Fibrosis stage and IGFBP analyses
Patients were classified according to 2 noninvasive methods for staging fibrosis: 
FibroTest and FibroScan. The 120 patients were divided into the following groups: 
F0 (n = 35), F1–F2 (n = 11–n = 14), F3 (n = 21), and F4 (n = 39). Significant dif-
ferences were found for IGFBP-2, IGFBP-4, IGFBP-5, and IGFBP-7 (Table 3). The 
differences were mainly between fibrosis grade and the control group for IGFBP-2 
and IGFBP 4. IGFBP-2, IGFBP-4, IGFBP-5, and IGFBP-7 concentrations correlated 
with the grade of fibrosis. There was an association between IGFBP-2 and fibrosis 
grade (Figure 1A), with an r of 0.263 (p = 0.001). IGFBP-4 was increased in F1–F2, 
F3, and F4, about the control subjects (Figure 1B). The correlation of IGFBP-4 
with fibrosis grade produced an r of 0.228, (p = 0.003). According to fibrosis grade, 
there were significant differences between F0 vs. F4 (p < 0.001) and F1-F2 vs. F3 
(p < 0.001) in the IGFBP-5 results (Figure 2A). We observed an oscillating pattern, 
given that stages F1–F2 and F4 had the highest concentrations.
There was a 2-fold greater increase in IGFBP-7 concentrations in patients, com-
pared with controls. Upon fibrosis grade evaluation, we found a gradual increase 
in the concentration of that protein (Figure 2B), obtaining significant differences 
between F0 vs. F3 (p < 0.001), F0 vs. F4 (p < 0.001), F1–F2 vs. F3 (p = 0.002), and 
F3 vs. F4 (p = 0.005) (Figure 2B). The correlation of IGFBP-7 with fibrosis grade 
Figure 1. 
IGFBP production in different fibrosis stages of CHC compared with healthy individuals. The concentration of 
IGFBPs (ng/mL) was determined at initial (F0), middle (F1–F2), and severe (F3 and F4) fibrosis stages in CHC 
and healthy individuals. (A) IGFBP-2 differences: a = F0vs CT (p = 0.002), b = F1–F2 vs. CT (p = 0.01), c = F3 vs. 
CT (p = 0.001), d = F4 vs. CT (p = 0.001). (B) IGFBP-4 differences: concentrations a = F1–F2 vs. CT (p = 0.002), 
b = F3 vs. CT (p = 0.008) and c = F4 vs. CT (p = 0.001). (C) IGFBP-5 differences: concentrations a = F4 vs. CT 
(p = 0.007), b = F0 vs. F4 (p < 0.001), c = F1–F2 vs. F3 (p < 0.001). (D) IGFBP-7 differences: concentrations 
a = F3 vs. CT (p = 0.001), b = F4 vs. CT (p < 0.001), c = F0 vs. F3 (p < 0.001), d = F0 vs. F4 (p = 0.008), e = F1–F2 
vs. F3 (p = 0.002) and f = F3 vs. F4 (p = 0.005). Data are expressed as mean ± standard error (SE).
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produced a statistically significant r of 0.384 (p = 0.001), indicating that IGFBP-7 
was associated with the grade of fibrosis, signifying that it could be a serologic 
biomarker for liver fibrosis.
Moreover, our study provides for first time completed screening of seven 
IGFBPs and their serum concentration in the initial, middle, and severe fibrosis 
stages. For IGFBP-1, slight differences in middle and severe stages and CT were 
found, whereas nonsignificant differences were observed for de IGFBP-3, and -6 
among F0, F1–F2, F3, F4, and CT classifications. However, evident variations 
were observed for IGFBP-2 and -4 according to the fibrosis degrees and CT group. 
(Table 3). The most evident concentration changes were observed in IGFBP-7, 
where the statistical analysis revealed a correlation in the fibrosis degrees and their 
production (Table 3).
6.1.3 Sensitivity and specificity of IGFBPs in severe fibrosis stage
Additionally, we performed calculation of the area under the receiver operat-
ing characteristic curve (AUROC) using the severe stage as a reference parameter 
with the aim to determine the sensitivity and specificity of IGFBP-2, -4, -5, and 
-7 with F4 stage (Figure 2 and Table 4). The results showed that the value of 
area under the curve for IGFBP-2 was 0.760 (p < 0.001; 95% CI, 0.672–0.847); 
whereas in IGFBP-4 was 0.744 (p < 0.001; 95% CI, 0.659–0.828), IGFBP-5 was 
0.600 (p = 0.049; 95% CI, 0.496–0.703), and for IGFBP-7 was 0.674 (p = 0.001; 
95% CI, 0.579–0.770) (Table 4). Based on the AUROC interpretation, where the 
Figure 2. 
ROC curve of the concentration of IGFBP-2, -4, -5, and -7 in patients with F4.
Protein Area 95%CI p
Lower limit Upper limit
IGFBP-2 (ng/mL) 0.760 0.672 0.847 0.000
IGFBP-4 (ng/mL) 0.744 0.659 0.828 0.000
IGFBP-5 (ng/mL) 0.600 0.496 0.703 0.049
IGFBP-7 (ng/mL) 0.674 0.579 0.770 0.001
Table 4. 
Evaluation of the area under the ROC curve of IGFBP-2, -4, -5, and -7 in patients with severe fibrosis degree 
(F4).
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values take more significance when they are close to the unit and with p value, we 
observed that the degree of predictive significance indicator of these proteins is: 
IGFBP2 < IGFBP-4 < IGFBP-7 < IGFBP-5.
7. Discussion
Our study is the first to quantify seven IGFBPs in patients with hepatitis C virus 
(HCV) and associate those protein levels with fibrosis grade. Different studies 
consider IGFBP-1 as an insulin-sensitive protein that participates in the develop-
ment of metabolic diseases, such as insulin-resistance or metabolic syndrome, in 
patients with or without liver disease. Some authors have reported elevated levels of 
IGFBP-1 expression [37], whereas others have found low levels [38, 39]. Because of 
findings of its increased expression, IGFBP-1 has been identified as a possible bio-
marker for alcoholic liver disease (ALD). Controversial results have been reported 
in relation to NAFLD. A decrease in serum concentrations due to interaction with 
insulin was described [40, 41], but Hagström et al. reported elevated values, with 
higher concentrations in patients with advanced fibrosis [19]. High concentrations 
have also been associated with hepatocellular carcinoma, albeit the role of that pro-
tein is still contradictory [37, 42]. In our study, IGFBP-1 concentrations were higher 
in subjects with CHC, but no differences were found in relation to fibrosis grade. 
However, studies on patients with liver cirrhosis of different etiologies (hepatitis 
C, hepatitis B, NAFLD, ALD, and autoimmune hepatitis) have shown that IGFBP-1 
increases [19, 43] and is higher in advanced fibrosis (F3 and F4) [19].
IGFBP-2 has been suggested as a biomarker for metabolic diseases, such as 
diabetes and insulin resistance [33]. In our study, IGFBP-2 concentrations were 
until 6-fold higher in patients, compared with controls. In accordance with fibrosis 
grade, there was also a gradual increase in IGFBP-2 concentration, but with no 
statistically significant differences between fibrosis stages, suggesting that IGFBP-2 
participates in liver damage and the development of fibrosis caused by HCV. Our 
results concur with those reported for idiopathic pulmonary fibrosis, in which high 
levels of IGFBP-2 were determined [44].
Additionally, in this work, we can determine for first time the evaluation of 
the specificity and sensibility of the seven IGFBPs. Interestingly, IGFBP-2 showed 
higher area values (AUROC) in F4 and thus can be considered as the best predictive 
IGFBP protein indicator in severe fibrosis stage followed by -4, -7 and -5.
IGFBP-3 had higher concentration levels than those of the other six IGFBPs. 
Nevertheless, the concentrations showed a tendency to be lower in patients than 
in controls. IGFBP-3 has been the most widely studied protein because of its high 
affinity for IGF-I. It has been described as a biomarker for liver dysfunction classi-
fied with the Child-Pugh scale, with a lower concentration in patients with Child-
Pugh class C [45]. Since 1995, many studies have been conducted on IGFBPs in 
patients with liver cirrhosis due to different causes. Results have shown a decrease in 
IGFBP-3 concentrations and an increase in IGF-I [46, 47]. IGFBPs are also thought 
to be associated with a high risk for liver cancer [48] and with poor prognosis [26]. 
Aleem et al. concluded that IGFBP-3 is superior to IGF-I and IGF-II for predicting 
the development of hepatocellular carcinoma in patients with cirrhosis caused by 
HCV [49], due to viral protein interaction that alters the IGF axis and the subse-
quent progression to liver cancer [50].
Miller et al. described the serum proteome of NAFLD, reporting increased 
IGFBP-3, compared with control subjects. They then analyzed fibrosis grade 
and severity and found that IGFBP-3 was able to distinguish between different 
disease stages [51]. In 2017, Chishima et al. studied the GH/IGF-I/IGFBP-3 axis 
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in patients with NAFLD and CHC and the relation to the histologic severity of 
NAFLD. IGFBP-3 levels were lower in patients with cirrhosis caused by NAFLD, 
whereas the levels did not decrease according to fibrosis grade in patients with HCV-
induced chronic liver disease [46]. Our results concurred with those of that study.
Cirrhosis alters IGF-I production and suppresses protein metabolism. In studies 
on children with end-stage liver disease (ESLD) who underwent liver transplanta-
tion, the authors concluded that their results partially explained the failure to growth 
and the reduced number of functioning hepatocytes in patients with ESLD [52].
IGFBP-4 has been associated with the progression of lung cancer, finding high 
expression of that protein in lung tissue, and showing a decrease in survival [53]. 
In our study, IGFBP-4 concentration was 2-fold higher in patients, compared with 
controls, and behavior fluctuated in relation to fibrosis grade, with no statistically 
significant differences. In a study on patients with ESLD, no differences in IGFBP-4 
were found upon comparison before and after liver transplantation [52]. In another 
study on cirrhotic patients and controls, there were no differences in IGFBP-4 when 
measured by the Western ligand blot technique [54]. Experimental studies have 
shown a regulation of the increase of that protein, along with IGFBP-1 and IGF-I, 
by AMPc, IL-6, IL-1β, and TNF-α [55, 56].
IGFBP-5 has been studied in animal models of progressive intrahepatic cholesta-
sis, suggesting that it plays a possible role in the pathogenesis of chronic cholangi-
opathy. The same authors reported that IGFBP-5, in human stellate cells (LX-2), 
increased pro-fibrotic marker expression, and concluded that IGFBP-5 participates 
in liver fibrosis progression [30]. In our study, IGFBP-5 concentrations were similar 
between patients and controls. However, upon classifying them by fibrosis grade, 
we found differences in F0 vs. F4 and F1–F2 vs. F3. These findings concur with 
the results reported by Colak et al. who showed that IGFBP-5 played an important 
role in many pathophysiologic stages of liver fibrosis [57]. One of the functions of 
IGFBP-5 was the trans-differentiation of HSCs into myofibroblasts, improving the 
survival of those cells through anti-apoptotic effects on the activated HSCs, increas-
ing collagen Iα1, TIMP-1, and MMP-1profibrotic gene expression.
It is known that IGFBP-6 can induce chemotaxis in T cells and monocytes, but 
not in B cells. It also increases oxidative stress and may be a late amplifier of neutro-
phil activation [58]. However, there have been few studies conducted on IGFBP-6 in 
liver diseases. In our study, IGFBP-6 concentrations were the same in patients and 
controls, and we found a tendency for concentrations to increase with the increase 
in fibrosis grade. IGFBP-6 has been described to be affected by HCV proteins and to 
participate in the progression to liver cancer [50, 59].
Finally, different studies demonstrate that IGFBP-7 (IGFBPrP1) contributes 
to liver fibrogenesis [27, 60, 61]. In our study, we found a significant increase in 
patients with liver disease. Likewise, we observed a gradual increase according to 
fibrosis grade. It was higher in F3, indicating that it could be a serum biomarker 
for liver fibrosis. IGFBP-7 has been widely studied in experimental models of liver 
fibrosis for identifying the mechanisms involved in the activation of HSCs and the 
signaling pathways, the result of which induces fibrosis. IGFBP-7 was inhibited in 
rat HSCs, inducing apoptosis in activated HSCs, and as a result, ameliorating liver 
fibrogenesis [61]. IGFBP-7 has also been shown to attenuate liver fibrosis through 
the regulation of MMPs/TIMPs in mice [62]. IGFBPrP1 contributed to the devel-
opment of liver fibrosis in fibrotic and cirrhotic tissue biopsy samples and may 
be a novel molecule involved in the progression of liver fibrogenesis [28]. Studies 
conducted in vitro found that IGFBPrP1 induced liver fibrosis by means of HSC 
activation and hepatocyte apoptosis through the Smad 2/3 signaling pathway [27]. 
In addition, it acted as an initiator of liver fibrosis by inducing inflammation, HSC 
activation, and ECM protein deposit through the ERK1/2 pathway [63]. IGFBPrP1 
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has also been shown to promote fibrosis, by enhancing the TGF-β1 expression that 
it triggered, and the Egr1, PTEN, Hhip, MAP2K2 (MEK2), and MAPK3 (ERK1) 
genes were identified as candidates for the hepatic fibrosis-related pathway 
induced by IGFBPrP1 [60]. Mutual IGFBPrP1 and TGF-β1 regulation has been 
found that probably accelerates liver fibrosis progression [64]. IGFBPrP1 inhibi-
tion attenuates fibrosis by reestablishing the MMP2/TIMP2 and MMP9/TIMP1 
balance concomitantly with the inhibition of HSC activation, low TGF-β1 expres-
sion, and ECM degradation [62]. Previous results, together with ours, show that 
IGFBP-7 is a molecule that can be diagnostically useful and a possible therapeutic 
target for liver fibrosis.
Currently, there are available treatment regiments against hepatitis C; in gen-
eral, these drugs have as specific targets viral proteins (e. g. NS3/4A, NS5A, and 
NS5B) inhibiting their replication. The ratio of efficacy of different combinations of 
drugs can reach until 95% of efficiency [65, 66]. Regarding the action of these drugs 
and liver fibrosis, it has been reported that peginterferon and/or ribavirin, dacla-
tasvir, sofosbuvir, and simeprevir can cause regression of liver fibrosis [67]. The 
specific molecular events induced by the administration of these drugs are not very 
well understood. However, it has been observed that the liver parenchymal injury 
and hepatocyte death are associated with the host’s inflammatory response and 
reactive oxygen species promoted by virus proteins [68, 69], whereby the elimina-
tion of viral load abrogates the subsequent liver damage. Nevertheless, the molecu-
lar mechanisms triggered by the pharmacological therapy in the IGF system are not 
evaluated until now; it is possible that tissue fibrosis reversion can be orchestrated 
by IGF elements such as the IGFBPs. Thus, the study of these proteins could have 
beneficial implication for diagnosis and as well as complementary target to improve 
the liver regeneration.
8. Conclusion
We found higher serum concentrations of IGFBP-2, IGFBP-4, IGFBP-5, and 
IGFBP-7 in patients with CHC, and in accordance with fibrosis grade, IGFBP-2, 
IGFBP-4, and IGFBP-7 are associated with severe fibrosis. Based on our study, we 
strongly suggest the possibility that IGFBPs participate in ECM protein modulation 
and reuptake and regulate the progression of chronic liver disease and development 
of liver fibrosis. Therefore, we believe that IGF binding proteins play an important 
role in chronic hepatitis C and can be serum marker candidates for liver fibrosis.
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